Rockwell Medical announces plans to price public offering of stock

Offering proceeds to funds clinical trials, general corporate purposes

By Toni Weeks

San Luis Obispo, Calif., May 14 - Rockwell Medical, Inc. announced in a 424B5 filing with the Securities and Exchange Commission its plans for a public offering of stock. There will be a 30-day greenshoe option.

Chardan Capital Markets, LLC is the bookrunner for the offering. Summer Street Research Partners is the lead manager, with C&Co/PrinceRidge as co-manager.

Proceeds will be used to fund clinical trials and for other general corporate purposes, which may include research and development expenses, acquisitions of intellectual property relating to complementary drug therapies and general and administrative expenses.

The Wixom, Mich., biopharmaceutical company focuses on products and services for end-stage renal disease and chronic kidney disease.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.